|
1
|
Wan DS: Epidemiologic trend of and
strategies for colorectal cancer. Ai Zheng. 28:897–902. 2009.(In
Chinese). PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weitz J, Koch M, Debus J, Höhler T, Galle
PR and Büchler MW: Colorectal cancer. Lancet. 365:153–165. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paul S: Dysfunction of the
ubiquitin-proteasome system in multiple disease conditions:
Therapeutic approaches. BioEssays. 30:1172–1184. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nakayama KI and Nakayama K: Regulation of
the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol.
16:323–333. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Salon C, Brambilla E, Brambilla C,
Lantuejoul S, Gazzeri S and Eymin B: Altered pattern of Cul-1
protein expression and neddylation in human lung tumours:
Relationships with CAND1 and cyclin E protein levels. J Pathol.
213:303–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen BB, Glasser JR, Coon TA and
Mallampalli RK: F-box protein FBXL2 exerts human lung tumor
suppressor-like activity by ubiquitin-mediated degradation of
cyclin D3 resulting in cell cycle arrest. Oncogene. 31:2566–2579.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen BB, Glasser JR, Coon TA, Zou C,
Miller HL, Fenton M, McDyer JF, Boyiadzis M and Mallampalli RK:
F-box protein FBXL2 targets cyclin D2 for ubiquitination and
degradation to inhibit leukemic cell proliferation. Blood.
119:3132–3141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang W, Chen Y, Deng J, Zhou J, Gu X, Tang
Y, Zhang G, Tan Y, Ge Z, Huang Y, et al: Cullin1 is a novel
prognostic marker and regulates the cell proliferation and
metastasis in colorectal cancer. J Cancer Res Clin Oncol.
141:1603–1612. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bai J, Zhou Y, Chen G, Zeng J, Ding J, Tan
Y, Zhou J and Li G: Overexpression of Cullin1 is associated with
poor prognosis of patients with gastric cancer. Hum Pathol.
42:375–383. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen G and Li G: Increased Cul1 expression
promotes melanoma cell proliferation through regulating p27
expression. Int J Oncol. 37:1339–1344. 2010.PubMed/NCBI
|
|
12
|
Chen G, Cheng Y, Martinka M and Li G: Cul1
expression is increased in early stages of human melanoma. Pigment
Cell Melanoma Res. 23:572–574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bai J, Yong HM, Chen FF, Mei PJ, Liu H, Li
C, Pan ZQ, Wu YP and Zheng JN: Cullin1 is a novel marker of poor
prognosis and a potential therapeutic target in human breast
cancer. Ann Oncol. 24:2016–2022. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
van Riggelen J, Yetil A and Felsher DW:
MYC as a regulator of ribosome biogenesis and protein synthesis.
Nat Rev Cancer. 10:301–309. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meyer KD, Donner AJ, Knuesel MT, York AG,
Espinosa JM and Taatjes DJ: Cooperative activity of cdk8 and GCN5L
within Mediator directs tandem phosphoacetylation of histone H3.
EMBO J. 27:1447–1457. 2008.PubMed/NCBI
|
|
17
|
Böckelman C, Koskensalo S, Hagström J,
Lundin M, Ristimäki A and Haglund C: CIP2A overexpression is
associated with c-Myc expression in colorectal cancer. Cancer Biol
Ther. 13:289–295. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
O'Hagan RC, Ohh M, David G, De Alboran IM,
Alt FW, Kaelin WG Jr and DePinho RA: Myc-enhanced expression of
Cul1 promotes ubiquitin-dependent proteolysis and cell cycle
progression. Genes Dev. 14:2185–2191. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang S, Wu X, Chen Y, Zhang J, Ding J,
Zhou Y, He S, Tan Y, Qiang F, Bai J, et al: Prognostic and
predictive role of JWA and XRCC1 expressions in gastric cancer.
Clin Cancer Res. 18:2987–2996. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang X, Takano Y and Zheng HC: The
pathobiological features of gastrointestinal cancers (Review).
Oncol Lett. 3:961–969. 2012.PubMed/NCBI
|
|
21
|
Xu M, Yang X, Zhao J, Zhang J, Zhang S,
Huang H, Liu Y and Liu J: High expression of Cullin1 indicates poor
prognosis for NSCLC patients. Pathol Res Pract. 210:397–401. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hatakeyama S, Watanabe M, Fujii Y and
Nakayama KI: Targeted destruction of c-Myc by an engineered
ubiquitin ligase suppresses cell transformation and tumor
formation. Cancer Res. 65:7874–7879. 2005.PubMed/NCBI
|
|
23
|
Blackburn JS, Liu S, Wilder JL, Dobrinski
KP, Lobbardi R, Moore FE, Martinez SA, Chen EY, Lee C and Langenau
DM: Clonal evolution enhances leukemia-propagating cell frequency
in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway
activation. Cancer Cell. 25:366–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee KS, Kwak Y, Nam KH, Kim DW, Kang SB,
Choe G, Kim WH and Lee HS: c-MYC copy-number gain is an independent
prognostic factor in patients with colorectal cancer. PLoS One.
10:e01397272015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khaleghian M, Shakoori A, Razavi AE and
Azimi C: Relationship of amplification and expression of the C-MYC
gene with survival among gastric cancer patients. Asian Pac J
Cancer Prev. 16:7061–7069. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zeng W, Sun H, Meng F and Liu Z, Xiong J,
Zhou S, Li F, Hu J, Hu Z and Liu Z: Nuclear C-MYC expression level
is associated with disease progression and potentially predictive
of two year overall survival in prostate cancer. Int J Clin Exp
Pathol. 8:1878–1888. 2015.PubMed/NCBI
|
|
27
|
Huang W, Guo L, Liu H, Zheng B, Ying J and
Lv N: C-MYC overexpression predicts aggressive transformation and a
poor outcome in mucosa-associated lymphoid tissue lymphomas. Int J
Clin Exp Pathol. 7:5634–5644. 2014.PubMed/NCBI
|
|
28
|
Zhang Y, Li J, Xi Y, Bai W, Bai W and Sun
R: Significance of C-myc expression in T-lymphoblastic
lymphoma/leukemia and its relation with prognosis. Zhonghua Bing Li
Xue Za Zhi. 44:571–577. 2015.PubMed/NCBI
|
|
29
|
Seo AN, Yang JM, Kim H, Jheon S, Kim K,
Lee CT, Jin Y, Yun S, Chung JH and Paik JH: Clinicopathologic and
prognostic significance of c-MYC copy number gain in lung
adenocarcinomas. Br J Cancer. 110:2688–2699. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Deming SL, Nass SJ, Dickson RB and Trock
BJ: C-myc amplification in breast cancer: A meta-analysis of its
occurrence and prognostic relevance. Br J Cancer. 83:1688–1695.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cepeda D, Ng HF, Sharifi HR, Mahmoudi S,
Cerrato VS, Fredlund E, Magnusson K, Nilsson H, Malyukova A,
Rantala J, et al: CDK-mediated activation of the SCFFBXO28
ubiquitin ligase promotes MYC-driven transcription and
tumourigenesis and predicts poor survival in breast cancer. EMBO
Mol Med. 5:1067–1086. 2013. View Article : Google Scholar : PubMed/NCBI
|
